申请人:——
公开号:US20030144523A1
公开(公告)日:2003-07-31
This invention relates to the new epothilone derivatives of general formula I,
1
in which
substituents Y, Z R
2a
, R
2b
, R
3
, R
4a
, R
4b
, D—E, R
5
, R
6
, R
7
, R
8
and X have the meanings that are indicated in more detail in the description.
The new compounds interact with tubulin by stabilizing microtubuli that are formed. They are able to influence the cell-splitting in a phase-specific manner and are suitable for treating malignant tumors, for example, ovarian, stomach, colon, adeno-, breast, lung, head and neck carcinomas, malignant melanomas, acute lymphocytic and myelocytic leukemia. In addition, they are suitable for anti-angiogenesis therapy as well as for treatment of chronic inflammatory diseases (psoriasis, arthritis). To avoid uncontrolled proliferation of cells and for better compatibility of medical implants, they can be applied or introduced into polymer materials.
The compounds according to the invention can be used alone or to achieve additive or synergistic actions in combination with other principles and classes of substances that can be used in tumor therapy.
本发明涉及具有通式I的新埃波替隆衍生物,其中取代基Y、Z、R2a、R2b、R3、R4a、R4b、D—E、R5、R6、R7、R8和X的含义在描述中更详细地指出。这些新化合物通过与微管蛋白的相互作用来稳定形成的微管。它们能够以阶段特异性的方式影响细胞分裂,并适用于治疗恶性肿瘤,例如卵巢、胃、结肠、腺体、乳腺、肺、头颈癌、恶性黑色素瘤、急性淋巴细胞和骨髓细胞白血病。此外,它们还适用于抗血管生成治疗以及治疗慢性炎性疾病(银屑病、关节炎)。为了避免细胞的不受控制的增殖以及提高医疗植入物的相容性,它们可以应用于或引入到聚合物材料中。根据发明的化合物可以单独使用,也可以与其他可用于肿瘤治疗的原理和物质类别结合使用,以实现相加或协同作用。